Key result
Daily subcutaneous injection of CNP-53 successfully restored glucocorticoid-induced growth retardation in a mouse model, with efficacy dependent on the age at which treatment was initiated.
Why the study?
Growth retardation is a significant side effect of glucocorticoid drugs used to treat pediatric diseases, prompting investigation into whether exogenous CNP-53 can treat this impairment.
Does exogenous CNP-53 improve skeletal growth in a murine model of glucocorticoid-induced growth retardation?
Does exogenous CNP-53 improve skeletal growth in a murine model of glucocorticoid-induced growth retardation?
Exogenous CNP-53 administration effectively restores glucocorticoid-induced growth retardation in a mouse model, with efficacy dependent on the age at which treatment is initiated.
Answers are grounded in this paper and cite their sources.
CNP-53 restored growth in glucocorticoid-treated juvenile mice; hypothesis-generating for pediatric use and requires clinical trials.
Growth retardation is an important side effect of glucocorticoid (GC)-based drugs, which are widely used in various preparations to treat many pediatric diseases. We investigated the therapeutic effect of exogenous CNP-53, a stable molecular form of intrinsic CNP, on a mouse model of GC-induced growth retardation. We found that CNP-53 successfully restored GC-induced growth retardation when both dexamethasone (DEX) and CNP-53 were injected from 4 to 8 weeks old. Notably, CNP-53 was not effective during the first week. From 4 to 5 weeks old, neither CNP-53 in advance of DEX, nor high-dose CNP-53 improved the effect of CNP. Conversely, when CNP-53 was started at 5 weeks old, final body length at 8 weeks old was comparable to that when CNP-53 was started at 4 weeks old. As for the mechanism of resistance to the CNP effect, DEX did not impair the production of cGMP induced by CNP. CNP reduced Erk phosphorylation even under treatment with DEX, while CNP did not changed that of p38 or GSK3β. Collectively, the effect of CNP-53 on GC-induced growth retardation is dependent on age in a mouse model, suggesting adequate and deliberate use of CNP would be effective for GC-induced growth retardation in clinical settings.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2019) studied Glucocorticoid-induced growth retardation. CNP-53 vs. Vehicle or Dexamethasone alone was evaluated on Naso-anal length and bone length (p=<0.05). Daily subcutaneous injection of CNP-53 successfully restored glucocorticoid-induced growth retardation in a mouse model, with efficacy dependent on the age at which treatment was initiated.
Synapse has enriched 10 related papers. Consider them for comparative context: